236 related articles for article (PubMed ID: 10821801)
1. Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022.
Kitano M; Norlén P; Ding XQ; Nakamura S; Håkanson R
Br J Pharmacol; 2000 Jun; 130(3):699-705. PubMed ID: 10821801
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the specificity and potency of a series of cholecystokinin-B/gastrin receptor antagonists in vivo.
Ding XQ; Håkanson R
Pharmacol Toxicol; 1996 Sep; 79(3):124-30. PubMed ID: 8884870
[TBL] [Abstract][Full Text] [Related]
3. Time-course of deactivation of rat stomach ECL cells following cholecystokinin B/gastrin receptor blockade.
Ding XQ; Lindström E; Håkanson R
Br J Pharmacol; 1997 Sep; 122(1):1-6. PubMed ID: 9298521
[TBL] [Abstract][Full Text] [Related]
4. CCK2 receptor antagonists: pharmacological tools to study the gastrin-ECL cell-parietal cell axis.
Håkanson R; Ding XQ; Norlén P; Lindström E
Regul Pept; 1999 Mar; 80(1-2):1-12. PubMed ID: 10235629
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin-B/gastrin receptor blockade suppresses the activity of rat stomach ECL cells.
Ding XQ; Lindström E; Håkanson R
Pharmacol Toxicol; 1997 Jul; 81(1):19-25. PubMed ID: 9258980
[TBL] [Abstract][Full Text] [Related]
6. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.
Takinami Y; Yuki H; Nishida A; Akuzawa S; Uchida A; Takemoto Y; Ohta M; Satoh M; Semple G; Miyata K
Aliment Pharmacol Ther; 1997 Feb; 11(1):113-20. PubMed ID: 9042983
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of three novel cholecystokinin-B/gastrin receptor antagonists: a study of their effects on rat stomach enterochromaffin-like cell activity.
Ding XQ; Lindström E; Håkanson R
Pharmacol Toxicol; 1997 Nov; 81(5):232-7. PubMed ID: 9396089
[TBL] [Abstract][Full Text] [Related]
8. YM022, a highly potent and selective CCKB antagonist inhibiting gastric acid secretion in the rat, the cat and isolated rabbit glands.
Attoub S; Moizo L; Laigneau JP; Alchepo B; Lewin MJ; Bado A
Fundam Clin Pharmacol; 1998; 12(3):256-62. PubMed ID: 9646057
[TBL] [Abstract][Full Text] [Related]
9. Effect of cholecystokinin-2 receptor blockade on rat stomach ECL cells. A histochemical, electron-microscopic and chemical study.
Chen D; Zhao CM; Norlén P; Björkqvist M; Ding XQ; Kitano M; Håkanson R
Cell Tissue Res; 2000 Jan; 299(1):81-95. PubMed ID: 10654072
[TBL] [Abstract][Full Text] [Related]
10. Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats.
Konagaya T; Bernsand M; Norlén P; Håkanson R
Br J Pharmacol; 2001 May; 133(1):37-42. PubMed ID: 11325792
[TBL] [Abstract][Full Text] [Related]
11. Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula.
Takemoto Y; Yuki H; Nishida A; Ito H; Kobayashi-Uchida A; Takinami Y; Akuzawa S; Ohta M; Satoh M; Semple G; Miyata K
Arzneimittelforschung; 1998 Apr; 48(4):403-7. PubMed ID: 9608884
[TBL] [Abstract][Full Text] [Related]
12. Effect of cholecystokinin-B/gastrin receptor blockade on gastric acid secretion in conscious rats.
Ding XQ; Håkanson R
Pharmacol Toxicol; 1996 Dec; 79(6):324-30. PubMed ID: 9000260
[TBL] [Abstract][Full Text] [Related]
13. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
[TBL] [Abstract][Full Text] [Related]
14. Sustained cholecystokinin-B/gastrin receptor blockade does not impair basal or histamine-stimulated acid secretion in chronic gastric fistula rats.
Ding XQ; Kitano M; Håkanson R
Pharmacol Toxicol; 1998 Apr; 82(4):177-82. PubMed ID: 9584331
[TBL] [Abstract][Full Text] [Related]
15. Effect of cholecystokinin receptor antagonists, MK-329 and L-365,260, on cholecystokinin-induced acid secretion and histidine decarboxylase activity in the rat.
Kawabata S; Kanayama S; Shinomura Y; Miyazaki Y; Imamura I; Moriwaki K; Wada H; Tarui S
Regul Pept; 1991 Jul; 35(1):1-10. PubMed ID: 1924892
[TBL] [Abstract][Full Text] [Related]
16. Reversibility of cholecystokinin-B/gastrin receptor blockade: a study of the gastrin-ECL cell axis in the rat.
Norlén P; Lindström E; Ding XQ; Kitano M; Håkanson R
Pharmacol Toxicol; 1999 Apr; 84(4):159-64. PubMed ID: 10227066
[TBL] [Abstract][Full Text] [Related]
17. YM022, a potent and selective gastrin/CCK-B receptor antagonist, inhibits peptone meal-induced gastric acid secretion in Heidenhain pouch dogs.
Yuki H; Nishida A; Miyake A; Ito H; Akuzawa S; Takinami Y; Takemoto Y; Miyata K
Dig Dis Sci; 1997 Apr; 42(4):707-14. PubMed ID: 9125636
[TBL] [Abstract][Full Text] [Related]
18. Role of gastrin in the development of gastric mucosa, ECL cells and A-like cells in newborn and young rats.
Björkqvist M; Dornonville de la Cour C; Zhao CM; Gagnemo-Persson R; Håkanson R; Norlén P
Regul Pept; 2002 Oct; 108(2-3):73-82. PubMed ID: 12220729
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
[TBL] [Abstract][Full Text] [Related]
20. Cholecystokinin-B receptor ligands of the dipeptoid series act as agonists on rat stomach histidine decarboxylase.
Ding XQ; Chen D; Håkanson R
Gastroenterology; 1995 Oct; 109(4):1181-7. PubMed ID: 7557084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
